A Swedish listed biotechnology company
Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).
Cantargia AB was formed in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukaemia stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research by Cantargia showed that this protein is also expressed in solid tumours present in many other types of cancer.
We are contributing to cancer treatments of the future
A lot of diseases are very complex, and despite extensive research, there is a considerable need for new treatments. Cancer is such a disease. Despite significant advances, cancer continues to be one of the most common causes of death, and a disease that is associated with considerable suffering.
At Cantargia we therefore see our job not only as important and challenging, but also as an opportunity to come up with more effective and better tolerated cancer treatments in the future. Our knowledge in the field of cancer research can also be applied to the development of products for other severe conditions, such as autoimmune and inflammatory diseases.
What makes our immunotherapy unique is its double mechanism of action: it both attacks cancer cells while counteracting the development of the tumour disease by inhibiting what is known as tumour inflammation.
Cantargia’s vision is to develop and secure the new-generation targeted drugs against IL1RAP as an important part of the more effective future cancer treatments. It is a vision that includes the development of new product candidates with the potential of also treating autoimmune/inflammatory diseases.
A Swedish biotechnology company whose science is based on research from Lund University
Vision of playing an important part in future cancer treatments
Experienced company management that has previously brought medicinal products to market
Noted on Nasdaq Stockholm’s main list (Small Cap)
Unique immunotherapy with a double mechanism of action
Highly relevant field of research with a clinically validated therapeutic mechanism
Scientific platform with many potential therapeutic areas
Robust patent portfolio